Rationale for the EUCAST clinical breakpoints

First Page		Document Content
Date: 2010-12-15 12:28:46 Health Organic chemistry Gram-negative bacteria Infectious diseases Microbiology Piperacillin Beta-lactamase Ertapenem Tazobactam Medicine Beta-lactam antibiotics Enterobacteria		Rationale for the EUCAST clinical breakpoints Add to Reading List Source URL: www.eucast.org Download Document from Source Website File Size: 370,39 KB Share Document on Facebook

	Microsoft Word - Arsanis_ASMMicrobe_Press_Release_6.17.16_FINAL_forWebsite.docx DocID: 1qhh2 - View Document
	Microorganisms Identified in Central Line-Associated Blood Stream Infections (CLABSI) in Illinois Hospital Intensive Care Units Reporting Period: /2014 A variety of organisms are found to contribute to c DocID: 1oYlM - View Document
	Carbapenem Non-Susceptible Cases in Utah, 2014 In May 2013, the Utah Department of Health (UDOH) changed the Communicable Disease Rule (Rule R386-702) to include reporting of certain healthcare-associated infections (HAI DocID: 1oCN0 - View Document
	MSSA Methicillin-(Oxacillin-) sensible Staphylococcus aureus MRSA Methicillin-(Oxacillin-) resistente Staphylococcus aureus 1 MRSA-Rate in Blutkulturen: 4% DocID: 1ntEe - View Document
	Epidemiological surveillance of carbapenemase producing enterobacteriacea (CPE) Lessons for the future Béatrice Jans & Prof. Youri Glupczynski DocID: 1aT6J - View Document